Resinate sustained release dextromethorphan composition

Details Resinate sustained release dextromethorphan composition Resinate sustained release dextromethorphan composition

1985-12-09

1988-11-29

Schenkman, Leonard

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

Polymer from ethylenic monomers only

514289, 514850, A61K 3174, A61K 3144

Patent

active

047880554

ABSTRACT:
A pharmaceutical preparation for controlled, sustained release of dextromethorphan comprising a polystyrene sulfonate resin which has been cross-linked with about 3% to about 10% divinyl benzene, having an average particle size of at least 48 .mu.m and less than 100 .mu.m onto which dextromethorphan has been loaded in a ratio of dextromethorphan hydrobromid to resin of about 1:3 to about 1:10 and at least one pharmaceutically acceptable adjuvant.

REFERENCES:
patent: 2990332 (1961-06-01), Keating
patent: 4221778 (1980-09-01), Raghunathan
patent: 4427681 (1984-01-01), Munshi
Remington's Pharmaceutical Sciences, 13th Edition, pp. 1625-1626.
Rohm and Haas Manufacture's Literature on Amberlite IRP69.
Amberlite Product Literature, Rohm & Haas (2/78).

Affiliated with

Also associated with

Rating

Resinate sustained release dextromethorphan composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Resinate sustained release dextromethorphan composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Resinate sustained release dextromethorphan composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-362661